Characteristics of 272 younger and 132 elderly AML patients
| . | Younger (test cohort) . | Elderly (validation cohort) . | ||||
|---|---|---|---|---|---|---|
| . | VTE . | AT . | No events . | VTE . | AT . | No events . |
| . | n = 9 . | n = 9 . | n = 254 . | n = 3 . | n = 8 . | n = 121 . |
| Male sex, n (%) | 2 (22) | 5 (56) | 135 (53) | 2 (67) | 4 (50) | 63 (52) |
| Mean age at enrollment, y (range) | 46 (24-60) | 48 (30-58) | 47 (18-65) | 67 (63-72) | 69 (61-74) | 68 (61-77) |
| Overall survival, mean in mo (range) | 31 (3-69) | 32 (1-79) | 28 (1-108) | 13 (4-14) | 7 (0-44) | 12 (0-158) |
| FAB | ||||||
| M0, n (%) | 0 | 0 | 13 (5) | 0 | 1(13) | 2 (2) |
| M1, n (%) | 1 (11) | 1 (11) | 39 (15) | 1 (33) | 2 (25) | 20 (17) |
| M2, n (%) | 3 (33) | 2 (22) | 70 (28) | 1 (33) | 1 (33) | 42 (35) |
| M4, n (%) | 1 (11) | 1 (11) | 30 (12) | 1 (33) | 3 (38) | 9 (7) |
| M5, n (%) | 3 (33) | 3 (33) | 40 (16) | 0 | 1 (33) | 11 (9) |
| M6, n (%) | 0 | 0 | 5 (2) | 0 | 0 | 7 (6) |
| RAEB, n (%) | 0 | 0 | 14 (6) | 0 | 0 | 9 (7) |
| RAEB-t, n (%) | 1 (11) | 2 (22) | 33 (13) | 0 | 0 | 20 (17) |
| Unknown, n (%) | 0 | 0 | 10 (4) | 0 | 0 | 1 (1) |
| Karyotype | ||||||
| t(8;21), n (%) | 1 (11) | 1 (11) | 7 (3) | 0 | 0 | 5 (4) |
| inv(16), n (%) | 0 | 0 | 15 (6) | 0 | 1 (13) | 4 (3) |
| CN –X-Y, n (%) | 3 (33) | 6 (67) | 132 (52) | 2 (67) | 3 (38) | 52 (43) |
| CA Rest, n (%) | 2 (22) | 1 (11) | 68 (27) | 1 (33) | 3 (38) | 43 (36) |
| MK, n (%) | 2 (22) | 1 (11) | 31 (12) | 0 | 0 | 14 (12) |
| Unknown, n (%) | 1 (11) | 0 | 1 (0) | 0 | 1 (13) | 3 (2) |
| Leukocytes, mean; range | 47.1 (1.7-175) | 18.5 (1.0-94) | 26.8 (0.5-232) | 45.1 (8.4-89) | 58.9 (1.2-144) | 26.6 (0.7-510) |
| Platelets, mean; range | 82 (29-212) | 107 (17-400) | 84 (6-701) | 74 (14-173) | 68.1 (32-109) | 84 (6-449) |
| Blasts in bone marrow, mean; range | 69 (10-97) | 62 (26-92) | 51 (2-97) | 74.3 (49-95) | 58.6 (29-95) | 44.9 (2-94) |
| DIC parameters* | ||||||
| D-dimer (mg/L), mean; range | 7.6 (0.2-18.5) | 3.3 (0.1-19.2) | 1.2 (0.0-18.5) | 2.2 (0.4-5.6) | 3.2 (0.3-8.7) | 1.2 (0.1-21.8) |
| PT (s), mean; range | 14.7 (11.8-19.8) | 15.0 (12.4-20.5) | 13.9 (10.9-35.3) | 15.3 (14.2-16.3) | 16.6 (11-26.7) | 13.9 (10.5-20.2) |
| Antithrombin (IU/mL), mean; range | 0.87 (0.51-1.23) | 0.89 (0.73-1.07) | 0.97 (0.40-1.41) | 0.8 (0.7-1.0) | 0.9 (06-1.1) | 0.9 (0.4-1.4) |
| Fibrinogen (g/L), mean; range | 3.2 (0.3-4.6) | 3.5 (2.2-4.4) | 4.2 (0.7-8.0) | 3.3 (3.3-3.3) | 3.8 (2.8-4.8) | 4.5 (1.7-9.7) |
| α-2-Antiplasmin (IU/mL), mean; range | 0.75 (0.15-1.11) | 0.99 (0.65-1.19) | 0.98 (0.37-1.52) | 1.0 (1.0-1.0) | 0.9 (0.8-1.1) | 1.0 (0.4-1.3) |
| Site of venous thrombosis | ||||||
| DVT of the leg, n | 2 | 1 | ||||
| Pulmonary embolism, n | 6 | 2 | ||||
| DVT upper extremity, n | 1 | 1 | ||||
| Site of arterial thrombosis | ||||||
| Myocardial infarction/acute coronary event, n | 3 | 3 | ||||
| CVA, n | 3 | 4 | ||||
| TIA, n | 1 | 0 | ||||
| Other, n | 2 | 1† | ||||
| Major bleeding n (%) | 0 (0) | 1 (5) | 21 (8) | 0 | 0 | 18 (15) |
| . | Younger (test cohort) . | Elderly (validation cohort) . | ||||
|---|---|---|---|---|---|---|
| . | VTE . | AT . | No events . | VTE . | AT . | No events . |
| . | n = 9 . | n = 9 . | n = 254 . | n = 3 . | n = 8 . | n = 121 . |
| Male sex, n (%) | 2 (22) | 5 (56) | 135 (53) | 2 (67) | 4 (50) | 63 (52) |
| Mean age at enrollment, y (range) | 46 (24-60) | 48 (30-58) | 47 (18-65) | 67 (63-72) | 69 (61-74) | 68 (61-77) |
| Overall survival, mean in mo (range) | 31 (3-69) | 32 (1-79) | 28 (1-108) | 13 (4-14) | 7 (0-44) | 12 (0-158) |
| FAB | ||||||
| M0, n (%) | 0 | 0 | 13 (5) | 0 | 1(13) | 2 (2) |
| M1, n (%) | 1 (11) | 1 (11) | 39 (15) | 1 (33) | 2 (25) | 20 (17) |
| M2, n (%) | 3 (33) | 2 (22) | 70 (28) | 1 (33) | 1 (33) | 42 (35) |
| M4, n (%) | 1 (11) | 1 (11) | 30 (12) | 1 (33) | 3 (38) | 9 (7) |
| M5, n (%) | 3 (33) | 3 (33) | 40 (16) | 0 | 1 (33) | 11 (9) |
| M6, n (%) | 0 | 0 | 5 (2) | 0 | 0 | 7 (6) |
| RAEB, n (%) | 0 | 0 | 14 (6) | 0 | 0 | 9 (7) |
| RAEB-t, n (%) | 1 (11) | 2 (22) | 33 (13) | 0 | 0 | 20 (17) |
| Unknown, n (%) | 0 | 0 | 10 (4) | 0 | 0 | 1 (1) |
| Karyotype | ||||||
| t(8;21), n (%) | 1 (11) | 1 (11) | 7 (3) | 0 | 0 | 5 (4) |
| inv(16), n (%) | 0 | 0 | 15 (6) | 0 | 1 (13) | 4 (3) |
| CN –X-Y, n (%) | 3 (33) | 6 (67) | 132 (52) | 2 (67) | 3 (38) | 52 (43) |
| CA Rest, n (%) | 2 (22) | 1 (11) | 68 (27) | 1 (33) | 3 (38) | 43 (36) |
| MK, n (%) | 2 (22) | 1 (11) | 31 (12) | 0 | 0 | 14 (12) |
| Unknown, n (%) | 1 (11) | 0 | 1 (0) | 0 | 1 (13) | 3 (2) |
| Leukocytes, mean; range | 47.1 (1.7-175) | 18.5 (1.0-94) | 26.8 (0.5-232) | 45.1 (8.4-89) | 58.9 (1.2-144) | 26.6 (0.7-510) |
| Platelets, mean; range | 82 (29-212) | 107 (17-400) | 84 (6-701) | 74 (14-173) | 68.1 (32-109) | 84 (6-449) |
| Blasts in bone marrow, mean; range | 69 (10-97) | 62 (26-92) | 51 (2-97) | 74.3 (49-95) | 58.6 (29-95) | 44.9 (2-94) |
| DIC parameters* | ||||||
| D-dimer (mg/L), mean; range | 7.6 (0.2-18.5) | 3.3 (0.1-19.2) | 1.2 (0.0-18.5) | 2.2 (0.4-5.6) | 3.2 (0.3-8.7) | 1.2 (0.1-21.8) |
| PT (s), mean; range | 14.7 (11.8-19.8) | 15.0 (12.4-20.5) | 13.9 (10.9-35.3) | 15.3 (14.2-16.3) | 16.6 (11-26.7) | 13.9 (10.5-20.2) |
| Antithrombin (IU/mL), mean; range | 0.87 (0.51-1.23) | 0.89 (0.73-1.07) | 0.97 (0.40-1.41) | 0.8 (0.7-1.0) | 0.9 (06-1.1) | 0.9 (0.4-1.4) |
| Fibrinogen (g/L), mean; range | 3.2 (0.3-4.6) | 3.5 (2.2-4.4) | 4.2 (0.7-8.0) | 3.3 (3.3-3.3) | 3.8 (2.8-4.8) | 4.5 (1.7-9.7) |
| α-2-Antiplasmin (IU/mL), mean; range | 0.75 (0.15-1.11) | 0.99 (0.65-1.19) | 0.98 (0.37-1.52) | 1.0 (1.0-1.0) | 0.9 (0.8-1.1) | 1.0 (0.4-1.3) |
| Site of venous thrombosis | ||||||
| DVT of the leg, n | 2 | 1 | ||||
| Pulmonary embolism, n | 6 | 2 | ||||
| DVT upper extremity, n | 1 | 1 | ||||
| Site of arterial thrombosis | ||||||
| Myocardial infarction/acute coronary event, n | 3 | 3 | ||||
| CVA, n | 3 | 4 | ||||
| TIA, n | 1 | 0 | ||||
| Other, n | 2 | 1† | ||||
| Major bleeding n (%) | 0 (0) | 1 (5) | 21 (8) | 0 | 0 | 18 (15) |